Jupiter Neurosciences, Inc. (JUNS)
| Market Cap | 3.69M -93.5% |
| Revenue (ttm) | 64,693 |
| Net Income | -9.20M |
| EPS | -18.57 |
| Shares Out | 1.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,224 |
| Open | 2.750 |
| Previous Close | 2.750 |
| Day's Range | 2.750 - 3.240 |
| 52-Week Range | 2.251 - 135.750 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About JUNS
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson’s disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alz... [Read more]
Financial Performance
Financial StatementsNews
Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson's Disease and Exploration of Strategic Options to Maximize Shareholder Value
First Patient Dosed with JOTROL ™ Marks Major Clinical Milestone for Jupiter Neurosciences' Phase 2a Study Evaluating Safety, Pharmacokinetics and Biomarkers of JOTROL ™ in Patients with Parkinson's D...
Jupiter Neurosciences files to sell 132,867 shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 132,867 shares of common stock. The company is not selling any…
Why Is Penny Stock Jupiter Neurosciences (JUNS) Up Today?
Jupiter Neurosciences stock was up 43.52% on Friday after the company announced a registered direct offering.
Jupiter Neurosciences announces pricing of $2M registered direct offering
Jupiter Neurosciences (JUNS) announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering. The gross…
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disord...
Jupiter Neurosciences Inc trading resumes
10:12 EDT Jupiter Neurosciences (JUNS) Inc trading resumes
Jupiter Neurosciences Inc trading halted, volatility trading pause
10:02 EDT Jupiter Neurosciences (JUNS) Inc trading halted, volatility trading pause
Jupiter Neurosciences Inc trading halted, news pending
19:50 EDT Jupiter Neurosciences (JUNS) Inc trading halted, news pending
Jupiter Neurosciences announces 1-for-75 reverse stock split
Jupiter Neurosciences (JUNS) announced that the board of directors of the company approved a 1-for-75 reverse stock split of the company’s common stock. The reverse split was approved by the…
Jupiter Neurosciences, Inc. Announces Reverse Stock Split
Jupiter's common stock is expected to begin trading on a post-split adjusted basis on August 7, 2026
Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a license agreement, enrollment completion and a patent filing. PHARMALA, JUPITER ENTE...
Jupiter Neurosciences Stock (JUNS) Jumps on a New License Deal
Jupiter Neurosciences ($JUNS) stock jumped on Tuesday after the clinical-stage pharmaceutical company announced a new licensing deal with PharmAla Biotech. This deal is for ALA-002, a clinical-stage c...
PharmAla enters up to $100M ALA-002 license pact with Jupiter Neurosciences
PharmAla (MDXXF) announced that it has entered into a definitive license agreement on July 20 with Jupiter Neurosciences (JUNS), under which PharmAla has granted Jupiter an exclusive, perpetual, royal...
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson's disease program
Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson
Former White House Council of Economic Advisors Brings Extensive Government, Academic, and Private Sector Experience to Advance Company's Strategic Growth
Jupiter Neurosciences files to sell 16M shares of common stock for holders
16:34 EDT Jupiter Neurosciences (JUNS) files to sell 16M shares of common stock for holders
Jupiter Neurosciences commences patient enrollment in RESET trial
Jupiter Neurosciences (JUNS) announced that patient enrollment is now underway in its Phase 2a RESET clinical trial for Jotrol in Parkinson’s Disease, with first patient dosing expected in the near…
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease
Investigational Oral Candidate JOTROL ™ Addresses a Parkinson's Disease Market with No Current Disease-modifying Therapies Available
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering
NEW YORK CITY, NY / ACCESS Newswire / May 26, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous syste...
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
Cash Runway Extended to Finance the Parkinson's Program; Debt Paydown Improves Shareholder Equity Position Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("J...
Jupiter Neurosciences announces pricing of $2M registered direct offering
Jupiter Neurosciences (JUNS) announced it has entered into a securities purchase agreement for the purchase and sale of 7.14M shares of common stock in a registered direct offering. The gross…
Jupiter Neurosciences to acquire licensing rights to ALA-002 for $3.33M upfront
Jupiter Neurosciences (JUNS) announced that it has entered into term sheet to acquire exclusive United States licensing rights to ALA-002, the drug candidate of PharmAla Biotech. Pursuant to the term…
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine
Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit
Jupiter, Florida--(Newsfile Corp. - May 4, 2026) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, announ...
Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14
Jupiter, Florida--(Newsfile Corp. - April 13, 2026) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, wil...